Health Trials

Recurrent Adamantinomatous Craniopharyngioma

2

Review clinical trials related to Recurrent Adamantinomatous Craniopharyngioma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.

Participants needed: 30
Trial details
Phase: Phase 2Age: 1-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: Apr 23, 2026Locations: 14
Eligibility criteria

Age: Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enr... [+24]

Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entere... [+14]

Read more
Status: Recruiting

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.

Participants needed: 38
Trial details
Phase: Phase 2Age: 1-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: Apr 8, 2026Locations: 10
Eligibility criteria

Age: Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enr... [+27]

Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entere... [+16]

Read more